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Impact of PTEN abnormalities on outcome in pediatric
patients with T-cell acute lymphoblastic leukemia treated on
the MRC UKALL2003 trial
S Jenkinson1, AA Kirkwood2, N Goulden3, A Vora4, DC Linch1 and RE Gale1
PTEN gene inactivation by mutation or deletion is common in pediatric T-cell acute lymphoblastic leukemia (T-ALL), but the impact
on outcome is unclear, particularly in patients with NOTCH1/FBXW7 mutations. We screened samples from 145 patients treated on
the MRC UKALL2003 trial for PTENmutations using heteroduplex analysis and gene deletions using single nucleotide polymorphism
arrays, and related genotype to response to therapy and long-term outcome. PTEN loss-of-function mutations/gene deletions were
detected in 22% (PTENABN). Quantiﬁcation of mutant level indicated that 67% of mutated cases harbored more than one mutant,
with up to four mutants detected, consistent with the presence of multiple leukemic sub-clones. Overall, 41% of PTENABN cases
were considered to have biallelic abnormalities (mutation and/or deletion) with complete loss of PTEN in a proportion of cells.
In addition, 9% of cases had N- or K-RAS mutations. Neither PTEN nor RAS genotype signiﬁcantly impacted on response to therapy
or long-term outcome, irrespective of mutant level, and there was no evidence that they changed the highly favorable outcome of
patients with double NOTCH1/FBXW7 mutations. These results indicate that, for pediatric patients treated according to current
protocols, routine screening for PTEN or RAS abnormalities at diagnosis is not warranted to further reﬁne risk stratiﬁcation.
Leukemia advance online publication, 21 August 2015; doi:10.1038/leu.2015.206
INTRODUCTION
Approximately 25% of pediatric patients with T-cell acute
lymphoblastic leukemia (T-ALL) are likely to relapse with recurrent
disease, and this presents a clinical challenge as post-relapse
prognosis is poor.1 A number of genetic abnormalities, including
mutations and copy number changes, have been identiﬁed at
disease presentation,2 and evidence suggests that most leukemic
blast cells at relapse are clonally related to those present at
diagnosis.3,4 This holds out promise, therefore, that molecular
proﬁling at diagnosis and identiﬁcation of factors that will predict
for relapse could improve outcome by facilitating targeted
therapy.5 NOTCH1 and FBXW7 gene mutations are frequent in
both pediatric and adult T-ALL, but although some studies have
demonstrated that their presence is associated with a favorable
outcome,6–8 others found no signiﬁcant effect.9–11 However,
recent studies have suggested that the impact of NOTCH1/FBXW7
mutations may be modulated by the presence of coincident
abnormalities such as in the phosphatase and tensin homolog
(PTEN) and RAS genes,12–14 and this implies that these genes
should routinely be characterized at diagnosis.
PTEN is the main negative regulator of the PI3K/AKT signaling
pathway and is implicated in regulating downstream effects of
NOTCH1 signaling such as proliferation and survival of T-cell
progenitors.15 Loss-of-function PTEN mutations leading to con-
stitutive activation of AKT were identiﬁed in T-ALL cell lines that
were resistant to NOTCH1 inhibition with γ-secretase inhibitors,16
and a number of studies have now described PTEN loss through
mutation and/or genomic deletion in up to 35% of pediatric
patients with T-ALL,12–14,17–21 although few studies have reported
both mutational and copy number status.12,14,18,21 The mutations
are predominantly clustered in exon 7 and are usually frameshift
indels that are predicted to lead to truncated proteins that retain
the 5’ phosphatase domain but are likely to be unstable.22 The
genomic deletions generally encompass the whole gene, although
microdeletions have recently been reported that result from
illegitimate RAG-mediated recombination events.23 In addition,
the abnormalities can be either monoallelic or biallelic for
mutation and/or deletion. RAS is also an important regulator of
proliferation through the RAS/RAF/MEK/ERK pathway, and
Kras-induced mouse models of T-cell leukemia/lymphoma show
a strong association with the development of NOTCH1
mutations.24,25 Activating N- and K-RAS mutations have been
reported in 4–10% T-ALL patients, particularly in early T-cell
precursor ALL.14,21,26,27
These studies suggest that PTEN and RAS abnormalities in T-ALL
may be suitable candidates as biomarkers and assist in directing
targeted therapy, but their prognostic impact in pediatric patients
is unclear, particularly in relation to their NOTCH1/FBXW7
genotype. In general, PTEN abnormalities in pediatric patients
are associated with non-signiﬁcantly worse outcome,12,13,23
although in adult patients, the impact was signiﬁcantly
adverse.14 However, whereas one study of pediatric patients
found that a trend for adverse impact was not seen in the
presence of a NOTCH1 mutation,13 the study of adult patients
reported that presence of a PTEN or RAS abnormality ablated the
beneﬁt of a NOTCH1 mutation.14 RAS mutations had no impact on
clinical outcome in a study of pediatric ALL, but no data were
given for the different subgroups.26
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In our study of 162 patients treated on the Medical
Research Council UKALL 2003 trial, we reported that patients
with double NOTCH1 or NOTCH1 and FBXW7 mutations
(NOTCH1± FBXW7Double) have a very good outcome and should
not be considered for more intensive therapy in ﬁrst remission,
even if slow responders or minimal residual disease (MRD) positive
after induction therapy.8 To determine whether PTEN and RAS
abnormalities impacted on this good outcome, and whether they
could reﬁne stratiﬁcation of cases with single NOTCH1 mutations
(NOTCH1Single) or wild-type NOTCH1 (NOTCH1WT), we investigated
PTEN and RAS genotype in samples from 145 patients treated on
this trial and evaluated their impact on outcome in the different
subgroups.
MATERIALS AND METHODS
Patients and treatment protocol
Diagnostic samples were available from 145 of the 388 (42%) T-ALL
patients entered into the UKALL2003 trial, excluding those with
bi-phenotypic leukemia or T-cell lymphoma. Ethical approval for the trial
was obtained from the Scottish Multi-Centre Research Ethics Committee
and informed consent in accordance with the Declaration of Helsinki. The
trial opened to patients aged 1–18 years in October 2003. The upper age
limit was increased to 20 in September 2006 and 25 in June 2008. Median
age of the patients studied was 9 years (range 1–23), 19 were more than 16
years, and only 5 (3%) were more than 18; 111 were male and 34 female.
Median follow-up was 6 years 9 months (range, 1–9.8 years).
The trial is registered at http://www.controlled-trials.com under ISRCTN
number 07355119. Details of the trial protocol have been published
elsewhere,28 and an outline is given in Supplementary Figure 1. Patients
with National Cancer Institute (NCI) low-risk score at trial entry (age 1–10
years and white blood cell count o50× 109/l) were allocated to regimen
A, those with high-risk score (age410 years and/or white blood cell count
450× 109/l) to regimen B. Patients with a slow early response (deﬁned as
425% bone marrow blasts at day 8 or 15 for high- and low-risk patients,
respectively) and o16 years of age were assigned to regimen C. At day 29,
patients not in morphological remission but with o25% blasts were also
reallocated to regimen C; those with resistant disease (425% blasts) were
taken off protocol and those with a rapid early response in morphological
remission were assessed for MRD using quantitative polymerase chain
reaction (PCR) analysis of leukemia clone-speciﬁc rearranged T-cell
receptor γ and δ genes.29 If MRD of more than 1 leukemic cell in 1000
cells (410− 3) was present, patients were classiﬁed as MRD-positive and
randomized to either remain on their assigned regimen (A or B) or to be
reallocated to regimen C. Of the 145 patients included in this study, 13
patients were treated on regimen A, 83 on B and 49 on C.
Mutation screening and mutant quantiﬁcation
Full experimental details are given in the Supplementary Data. The entire
coding sequence of the PTEN gene (exons 1–9) and exons 2 and 3 of the
N-RAS and K-RAS genes were screened by PCR of genomic DNA and
heteroduplex analysis on the WAVE DNA Fragment Analysis System
(Transgenomic, Glasgow, UK). Samples with abnormal chromatograms
were sequenced. Where this showed either multiple or low-level
mutations, amplicons were cloned using the TOPO TA cloning kit
(Invitrogen, Paisley, UK) and sequenced. Exon 7 mutants were sized and
quantiﬁed by fragment analysis of ﬂuorescently labeled PCR products
using both genomic DNA where available and whole genome ampliﬁed
DNA (see Supplementary Data). Mutant level was expressed as a
percentage of total PTEN alleles. Cases with o5% total mutant were
scored as wild type (WT).
CytoSNP-850k SNP array analysis
Whole genome ampliﬁed DNA was used to determine genome-wide copy
number on the Inﬁnium CytoSNP-850k Beadchip array (Illumina, Essex, UK)
according to the manufacturer’s protocols. The data were analyzed using
the Genotyping Module of the GenomeStudio software to calculate log R
intensities and B-allele frequencies for each of the 230 single nucleotide
polymorphism (SNP) markers covering the PTEN gene (chromosome 10:
89612850-89721667). Each sample was independently assessed for PTEN
copy number changes by two individuals and scored as WT, heterozygous
deletion or homozygous deletion.
SNP allele quantiﬁcation
Relative allele levels for the A/G SNP rs1903858 in intron 1–2 and the
T/G SNP rs555895 in intron 8–9 were quantiﬁed using allele-speciﬁc
restriction enzyme digestion and fragment analysis of ﬂuorescently labeled
PCR products (see Supplementary Data). A normal range using samples
from 20 SNP-positive hematologically normal controls was ﬁrst established;
the mean allele A% for rs1903858 was 53± 2% (range, 50–58%), and the
mean allele T% for rs555895 was 53± 2% (range, 49–57%). Any deviation
from this range was considered to indicate loss of genomic material.
Type 1 microdeletions
To screen for type 1 microdeletions as reported by Mendes et al.,23 PCR
was performed with primers in introns 1–2 and 3–4 just outside of the
breakpoint junction (see Supplementary Data). Resulting products were
sequenced.
Cytogenetic and ﬂuorescence in situ hybridization analysis
Cytogenetic and ﬂuorescence in situ hybridization analyses were
performed as previously described.7
Statistical analysis
Kaplan–Meier curves were used to assess overall survival (OS; the time
from randomization to death), event-free survival (the time to relapse,
secondary tumor or death, whichever came ﬁrst) and relapse-free survival
(the time to relapse or ALL death in those who achieved remission).
Patients who did not experience an event were censored at the date last
seen. Differences between groups were compared using the log-rank test.
All P-values quoted are two-sided. Analyses were performed using Stata
version 12.1 (Stata Corp, College Station, TX, USA).
RESULTS
PTEN mutation analysis
Mutation screening. A total of 44 PTEN mutations were identiﬁed
in 21 of the 145 patients investigated (14%, PTENMUT), 40 in exon
7, 2 in exon 6 and 2 in exon 5 (Supplementary Table 1). Nineteen
cases (90%) had exon 7 mutations, two of which also had exon 6
mutations, and two (10%) had just exon 5 mutations (Figure 1a).
The mutations included insertions, deletions and indels, with
overall size changes ranging between 1 and 20 bps. In 34 (77%),
the size change would cause a frameshift, and 10 (23%) were
in-frame. Of the 39 with available sequence, 31 (79%) led to
truncation of the C-terminus through a nonsense mutation or
introduction of a premature stop codon, 8 (21%) were in-frame
and non-truncating. Of note, of the 21 mutated cases, only 7 (33%)
had a single mutant; 8 (38%) had two mutants, and 3 cases (14%)
each had three or four mutants (Figure 1b).
Mutant level quantiﬁcation. Exon 7 mutant levels were quantiﬁed
using both genomic DNA and whole genome ampliﬁed DNA;
highly comparable results were obtained (Supplementary Figure 2).
The mean mutant level for individual mutants was 20% (range,
2–48%). For the exon 5 and 6 mutants, an estimated mutant level
was determined from the sequence peak heights. The median
total mutant level for the 21 PTENMUT cases was 48% (range,
10–96%); 5 cases (24%) had ⩽ 25% total mutant, 6 (29%) had
26–50% and 10 (47%) had 450% (Figure 1c). Where multiple
mutations were detected, it was not possible to determine
whether these mutants were in the same or different cell
populations.
PTEN copy number analysis
SNP arrays. Interpretable results were obtained from Illumina
CytoSNP-850k SNP array analysis of 139 samples. Genomic loss of
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the PTEN gene was detected in 14 patients (10%) and scored as
heterozygous loss in 11 cases and homozygous loss in 3 cases
(Supplementary Figure 3). A further four cases had evidence of
ampliﬁcation of the PTEN gene, but as they did not demonstrate
loss-of-function and the consequence of the ampliﬁcation was not
known, they were scored as WT for the purposes of this study.
In all cases, the deletion looked to encompass the whole gene.
SNP allele quantiﬁcation. In 72 of the 145 samples (50%), it was
possible to validate the array data and quantify the level of
heterozygous loss by measuring the relative allele levels of two
common intronic SNPs in introns 1–2 (rs1903858) and 8–9
(rs555895) (Figure 2). Consistent SNP array and SNP allele
quantiﬁcation results were obtained in 70 cases (97%), including
64 WT, 3 with ampliﬁcation and 3 with heterozygous deletion.
However, in two cases that were initially scored as WT on the
array, SNP allele quantiﬁcation indicated loss at the 3’ end of the
gene. The deletions were conﬁrmed by re-evaluation of the array
data. SNP allele quantiﬁcation data were also obtained on four
cases without array data, three were WT and one had a
heterozygous deletion. Of the six quantiﬁable cases with genomic
loss, the SNP allele ratios were consistent with heterozygous
deletion in at least half of the cells (range, 46–94%) (Figure 2,
Supplementary Table 1).
Type 1 microdeletions. Type 1 microdeletions, removing a 65 kb
region encompassing exons 2 and 3,21 were detected in four of
the 145 patients (3%) and had not been detected by the SNP
array. However, all four patients harbored other PTEN abnormal-
ities. One had a homozygous deletion, one a heterozygous
deletion and two had mutations with o20% total mutant level
(Supplementary Table 1). Although it was not possible to
determine the level of the microdeletions, in each case, the
intensity of the PCR product was more likely to indicate their
presence in minor sub-clones.
Combined PTEN genotype
Overall, 143 patients had PTEN mutation and deletion status;
deletion status was not available for the two remaining patients
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Figure 1. Characteristics of PTEN mutations detected. (a) Schematic representation of the location and type of mutations detected for the 39
mutants with available sequence. (b) Quantiﬁcation of mutant level by fragment analysis, showing cases with 1–4 mutants. The level is given
as a percentage of total alleles. (c) Distribution of total PTEN mutant level detected in mutant-positive patients. Del, deletion; ins, insertion.
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Figure 2. Representative SNP allele quantiﬁcation at loci in PTEN intron 1–2 (rs1903858) and intron 8–9 (rs555895) in samples from a normal
control and two patients with heterozygous loss.
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but both were PTENMUT. In total, therefore, 32 patients (22%) had
PTEN abnormalities (PTENABN), comprising 17 PTENMUT (53% of
PTENABN cases), 11 (34%) with genomic deletion (PTENDEL)
and 4 (13%) with both mutation and deletion (PTENMUT+DEL).
Of the 21 PTENMUT cases, 11 were considered to harbor
monoallelic mutations (PTENMONO) as the total mutant level
was o50% of total alleles and there was either a single
heterozygous clone (one mutant, level 37–48%, that is, present in
most cells) or multiple sub-clones (more than one mutant,
individual level 2–21%) (Supplementary Table 1). The remaining
10 PTENMUT patients were considered to harbor biallelic
mutations (PTENBI) as all had 450% total mutant consistent
with either a single homozygous or hemizygous mutation or
compound heterozygous mutations in at least some of the cells.
Therefore, for the combined PTENMUT and PTENDEL genotype, 19
patients (59%) were scored as PTENMONO and 13 patients (41%)
as PTENBI.
RAS mutation screening
Missense RAS mutations (RASMUT) were detected in 13 (9%) of the
145 patients analyzed, 8 in N-RAS (4 G12D, 1 each G12V, G13C,
G13R and Y64N) and 5 in K-RAS (2 G12C, 1 each G12S, A18D and
Y64D). Only 1 of the 32 PTENABN patients (3%) had a RAS mutation.
Therefore, 44 patients (30%) were PTEN/RASABN.
Characteristics of T-ALL patients according to PTEN and RAS
genotype
There was no signiﬁcant difference in sex, white blood cell count,
age group, NCI risk group or cytogenetic characteristics between
PTENABN and PTENWT patients (Table 1). However, PTENABN patients
had a signiﬁcantly higher incidence of CNS disease than PTENWT
patients (P= 0.04). No signiﬁcant differences were observed
according to RAS genotype.
Table 1. Characteristics of cohort studied according to PTEN and RAS genotype
Subgroup Total PTEN genotype RAS genotype
PTENWT(n= 113) PTENABN(n= 32) Pa RASWT(n= 132) RASMUT(n= 13) Pa
No. (%)b No. (%)b No. (%)b No. (%)b
Gender 0.48 0.3
Male 111 85 (75%) 26 (81%) 99 (75%) 12 (92%)
Female 34 28 (25%) 6 (19%) 33 (25%) 1 (8%)
WBC (x109/l) 0.15 0.79
o50 47 41 (36%) 6 (19%) 42 (32%) 5 (38%)
50–99 22 17 (15%) 5 (16%) 21 (16%) 1 (8%)
⩾ 100 76 55 (49%) 21 (66%) 69 (52%) 7 (54%)
Median count 110.5 95 135.7 108.25 167.1
Range 0.5–881.0 0.5–881.0 0.7–777 0.7–881.0 0.5–456.5
Age group (years) 0.1 0.5
o10 79 56 (50%) 23 (72%) 72 (55%) 7 (54%)
15-Oct 47 40 (35%) 7 (22%) 44 (33%) 3 (23%)
⩾ 16 19 17 (15%) 2 (6%) 16 (12%) 3(23%)
Median 9 10 8.5 9 9
Range 1–23 1–23 1–18 1–23 4–23
CNS disease 0.04 40.99
No 135 110 (97%) 28 (88%) 125 (95%) 13 (100%)
Yes 7 3 (3%) 4 (12%) 7 (5%) 0
NCI risk group 0.99 0.67
Low 18 14 (12%) 4 (13%) 16 (12%) 2 (15%)
High 127 99 (88%) 28 (88%) 116 (88%) 11 (85%)
Treatment regimen (risk) 0.87 0.23
A (low/standard) 13 10 (9%) 3 (9%) 11 (8%) 2 (15%)
B (intermediate) 83 66 (58%) 17 (53%) 78 (59%) 5 (38%)
C (high) 49 37 (33%) 12 (38%) 43 (33%) 6 (46%)
Cytogenetics 0.86c,d 40.99d
Normal 28 21 (19%) 7 (22%) 26 (20%) 2 (15%)
Abnormal 90 69 (61%) 21 (66%) 81 (61%) 9 (69%)
Failed/missing 27 23 (20%) 4 (13%) 25 (19%) 2 (15%)
Genetic subgroup N/A N/A
AF10-CALM 3 3 (3%) 0 2 (2%) 1 (8%)
LMO2 10 8 (7%) 2 (6%) 9 (7%) 1 (8%)
MLL 3 3 (3%) 0 3 (2%) 0
TAL1 14 8 (7%) 6 (19%) 14 (11%) 0
TLX1 5 4 (4%) 1 (3%) 5 (4%) 0
TLX3 15 14 (12%) 1 (3%) 11 (8%) 4 (31%)
Other/unclassiﬁed 95 73 (65%) 22 (69%) 88 (67%) 7 (54%)
CDKN2A/B deletion 0.29 0.2
No 45 36 (32%) 9 (28%) 39 (30%) 6 (46%)
Yes 79 56 (50%) 23 (72%) 74 (56%) 5 (38%)
Missing 21 21 (19%) 0 19 (14%) 2 (15%)
Abbreviations: ABN, abnormal; CNS, central nervous system; NCI, National Cancer Institute; N/A, not applicable; MUT, mutant; WT, wild type; WBC, white blood
cell count. aP-values: Fisher’s exact test unless otherwise indicated. bPercentages may not add up to 100 owing to rounding up. cChi squared test. dExcludes
missing/failed.
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Prognostic relevance of PTEN abnormalities and RAS mutations
Response to therapy. Response to therapy data was available for
all patients, and the incidence of a slow early response did not
statistically differ according to the PTEN, RAS or combined PTEN/
RAS genotype (Table 2). MRD status at day 29 post diagnosis
was available for 134 patients, and no statistically signiﬁcant
differences were seen in the frequency of unfavorable disease
according to the different genotype groups (Table 2). When the
data were stratiﬁed according to the level of PTEN abnormality,
there was a suggestion that patients with PTENMONO had the
highest levels of MRD, but the subgroups were small and this
could have occurred by chance.
Long-term outcome. Event-free survival, relapse-free survival and
OS were slightly worse for PTENABN compared with PTENWT cases
(Figures 3a and b) (Table 2). However, the difference only showed
a borderline trend for signiﬁcance for OS (81 versus 91% at
5 years; hazard ratio (95% conﬁdence interval), 2.27 (0.82–6.24);
P= 0.10), there were only a small number of events, and the
conﬁdence intervals for all analyses were wide. There was no
difference in the relative proportion of PTENABN and PTENWT
patients treated on the different regimens (Table 1). When
patients were stratiﬁed according to PTEN mutant level, PTENMONO
had the lowest event-free survival and OS, but the number of
patients in these groups was small and the differences were not
signiﬁcant across the three groups (Table 2) (Figures 3c and d).
Similarly, outcome did not differ in the RAS genotypic groups
(Supplementary Figures 4A and B), or in the combined PTEN/RAS
groups (Figures 3e and f).
NOTCH1/FBXW7/PTEN/RAS genotype of T-ALL patients
We have previously shown that outcome in this cohort differs
according to the NOTCH1/FBXW7 genotype, with a very good
outcome in the NOTCH1± FBXW7Double group.8 We therefore
examined whether PTEN or RAS genotype changed this. The
incidence of PTEN abnormalities did not differ according to
NOTCH1/FBXW7 genotype (59% PTENABN patients had a NOTCH1
and/or FBXW7 mutation compared with 68% PTENWT patients;
P= 0.35), nor did RAS genotype (77% for RASMUT versus 65% for
RASWT; P= 0.54) or the combined PTEN/RAS genotype (59% for
PTEN/RASABN versus 65% for PTEN/RASWT; P= 0.67). There were also
no differences in PTEN and/or RAS genotype when the patients
were grouped into the three previously deﬁned NOTCH1/FBXW7
genotype groups, NOTCH1WTFBXW7WT, NOTCH1SingleFBXW7WT and
NOTCH1± FBXW7Double, excluding the four patients with an FBXW7
mutation only (Supplementary Table 2).
Of the 37 NOTCH1± FBXW7Double patients, 9 (24%) had PTEN
and/or RAS abnormalities (5 PTENABN and 5 RASMUT, 1 with both),
but this did not impact on their favorable outcome, as all were
alive at 5 years (Table 3). Only two patients relapsed, both in the
PTEN/RASWT group. In the NOTCH1SingleFBXW7WT group, 17 of the
55 patients (31%) were PTEN/RASABN (14 PTENABN, 3 RASMUT), and
although OS was slightly lower than in the PTEN/RASWT patients,
none of the differences were signiﬁcant (Table 3). Overall, OS and
relapse-free survival were lowest for PTEN/RASABN patients in the
NOTCH1WTFBXW7WT group (16 of 49 patients (33%); 13 PTENABN, 3
RASMUT), but did not signiﬁcantly differ from PTEN/RASWT patients
in this group (Figure 3f).
In a study of adult cases, a low-risk group, deﬁned as NOTCH1-
mutant and/or FBXW7-mutant without a PTEN or RAS mutation,
had a signiﬁcantly better outcome than the high-risk group of all
other cases combined together.14 Using this stratiﬁcation system,
there was no signiﬁcant difference in relapse-free survival in our
cohort (87% for both), although there was a slightly improved OS
in the low-risk group (94 versus 84%; P= 0.06) (Supplementary
Figures 5A and B). T
ab
le
2.
R
es
p
o
n
se
to
ch
em
o
th
er
ap
y
an
d
su
rv
iv
al
st
at
u
s
ac
co
rd
in
g
to
PT
EN
/R
A
S
g
en
o
ty
p
e
O
ve
ra
ll
PT
EN
ge
no
ty
pe
PT
EN
W
T/
m
on
oa
lle
lic
/b
ia
lle
lic
O
ve
ra
ll
RA
S
ge
no
ty
pe
PT
EN
/R
A
S
ge
no
ty
pe
N
o.
PT
EN
W
T (
n
=
11
3)
PT
EN
A
B
N
(n
=
32
)
Pa
PT
EN
W
T (
n
=
11
3)
PT
EN
M
O
N
O
(n
=
19
)
PT
EN
B
I (n
=
13
)
Pa
,b
RA
SW
T (
n
=
13
2)
RA
SM
U
T (
n
=
13
)
Pa
PT
EN
/
RA
SW
T (
n
=
10
1)
PT
EN
/
RA
SA
B
N
(n
=
44
)
Pa
SE
R N
o
10
8
84
(7
4%
)
24
(7
5%
)
0.
94
84
(7
4%
)
14
(7
4%
)
10
(7
0%
)
4
0.
99
c
10
0
(7
6%
)
8
(6
2%
)
0.
32
c
77
(7
6%
)
31
(7
0%
)
0.
46
Ye
s
37
29
(2
6%
)
8
(2
5%
)
29
(2
6%
)
5
(2
6%
)
3
(3
0%
)
32
(2
4%
)
5
(3
8%
)
24
(2
4%
)
13
(3
0%
)
M
RD
at
da
y
29
N
eg
at
iv
e
72
60
(5
6%
)
12
(4
4%
)
0.
28
60
(5
6%
)
5
(3
1%
)
7
(6
4%
)
0.
69
b
66
(5
5%
)
6
(4
6%
)
0.
56
54
(5
7%
)
18
(4
6%
)
0.
26
Po
si
ti
ve
62
47
(4
4%
)
15
(5
6%
)
47
(4
4%
)
11
(6
9%
)
4
(3
6%
)
55
(4
5%
)
7
(5
4%
)
41
(4
3%
)
21
(5
4%
)
Ev
en
ts
/n
,5
-y
ea
r
ou
tc
om
e,
%
(9
5%
CI
)
R
FS
14
4
14
/1
13
5/
31
0.
55
d
14
/1
13
3/
18
2/
13
0.
60
b
,d
18
/1
31
1/
13
0.
54
d
13
/1
01
6/
43
0.
83
d
87
%
84
%
87
%
83
%
85
%
86
%
92
%
87
%
86
%
(8
0–
92
%
)
(6
6–
93
%
)
(8
0–
92
%
)
(5
7–
94
%
)
(5
1–
96
%
)
(7
9–
91
%
)
(5
7–
99
%
)
(7
8-
92
%
)
(7
2-
94
%
)
EF
S
14
5
18
/1
13
7/
32
0.
37
d
18
/1
13
5/
19
2/
13
0.
61
b
,d
22
/1
32
2/
13
0.
83
d
17
/1
01
8/
44
0.
77
d
85
%
78
%
85
%
74
%
85
%
84
%
85
%
84
%
82
%
(7
7–
90
%
)
(6
0–
90
%
)
(7
7–
90
%
)
(4
8–
88
%
)
(5
1–
96
%
)
(7
6–
89
%
)
(5
1–
96
%
)
(7
6-
90
%
)
(6
7-
91
%
)
O
S
14
5
10
/1
13
6/
32
0.
10
d
10
/1
13
4/
19
2/
13
0.
20
b
,d
15
/1
32
1/
13
0.
69
d
9/
10
1
7/
44
0.
20
d
91
%
81
%
91
%
79
%
85
%
89
%
92
%
91
%
84
%
(8
4–
95
%
)
(6
3–
91
%
)
(8
4–
95
%
)
(5
3–
92
%
)
(5
1–
96
%
)
(8
2–
93
%
)
(5
7–
99
%
)
(8
4-
95
%
)
(7
0-
92
%
)
A
b
b
re
vi
at
io
n
s:
A
B
N
,
ab
n
o
rm
al
;
B
I,
b
ia
lle
lic
;
C
I,
co
n
ﬁ
d
en
ce
in
te
rv
al
;
EF
S,
ev
en
t-
fr
ee
su
rv
iv
al
;
M
O
N
O
,
m
o
n
o
al
le
lic
;
M
R
D
,
m
in
im
al
re
si
d
u
al
d
is
ea
se
;
O
S,
o
ve
ra
ll
su
rv
iv
al
;
R
FS
,
re
la
p
se
-f
re
e
su
rv
iv
al
;
SE
R
,
sl
o
w
ea
rl
y
re
sp
o
n
se
;
W
T,
w
ild
ty
p
e.
a P
-v
al
u
es
:C
h
i-s
q
u
ar
ed
te
st
u
n
le
ss
o
th
er
w
is
e
in
d
ic
at
ed
.b
Te
st
fo
r
tr
en
d
ac
ro
ss
PT
EN
W
T
,P
TE
N
M
O
N
O
an
d
PT
EN
B
I
g
ro
u
p
s.
c F
is
h
er
’s
ex
ac
t
te
st
.d
Lo
g
-r
an
k
te
st
.
Impact of PTEN abnormalities in pediatric T-ALL
S Jenkinson et al
5
© 2015 Macmillan Publishers Limited Leukemia (2015) 1 – 9
DISCUSSION
PTEN is a tumor-suppressor gene that is frequently inactivated in a
wide variety of cancers leading to hyperactivation of the PI3K/AKT
signaling pathway.30 It has an important role in the proliferation
and survival of T-cell progenitors,15 and its loss may sustain
leukemic T-cell viability in T-ALL.31 Furthermore, studies have
associated PTEN genetic abnormalities with glucocorticoid resis-
tance, one of the main causes of relapse in T-ALL, and sensitivity
can be re-instated by inhibiting PI3K or AKT.32,33 Knowledge of
PTEN genotype may therefore help to reﬁne current risk
stratiﬁcation strategies that are based on response to therapy,
and inform clinical decisions. The available information to date
suggests that PTEN abnormalities appear to be associated with
adverse outcome in T-ALL, but the data are limited; the cohorts in
some studies are small, not all studies have examined both
mutations and deletions, and most studies have not considered
the impact of the mutant level, in particular whether those with
complete (biallelic) PTEN loss differ from those with partial
(monoallelic) loss. In addition, contradictory results have been
reported in pediatric and adult patients for the impact of the
abnormalities in the NOTCH1/FBXW7-mutated subgroup,13,14
which is important for clinical application as at least some studies
91%
81%
91%
85%
79%
87%
84%
87%
83%85%
91%
84%
87%
86%
Figure 3. Kaplan–Meier curves for relapse-free survival (a, c, e) and overall survival (b, d, f) stratiﬁed according to PTEN and RAS genotype.
(a, b) PTENABN and PTENWT. (c, d) PTENWT, PTENMONO and PTENBI. (e, f) PTEN/RASABN and PTEN/RASWT. ABN, abnormal; BI, biallelic; MONO,
monoallelic.
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have shown that patients with NOTCH1/FBXW7 mutations do
particularly well.6–8 There is also no information on the impact of
RAS mutations in pediatric T-ALL, although in adult patients, they
were associated with worse outcome and were included as poor
risk in an oncogenetic classiﬁer strategy.14
In the present study, inactivating PTEN mutations were detected
in 14% of the cohort and gene deletions in 10%, with an overall
incidence of 22% with PTEN gene abnormalities, which is in
keeping with the combined data from other pediatric studies of
16% with mutations,13,18,20,23 6% with deletions,18,19,23 and 20%
for mutations and/or deletions.18,23 In common with the other
studies, the mutations detected were predominantly located in
exon 7 and were truncating mutations predicted to lead to
haploinsufﬁciency, rather than the dominant-negative missense
mutations that often occur in other types of cancer and that were
associated with a more complete loss of PTEN activity and
accelerated tumorigenesis in a mouse model.34 We have also
screened for type 1 microdeletions as reported by Mendes et al.,23
but they were only detected in 3% of the patients and did not
change the PTEN classiﬁcation as all four positive cases had other
PTEN abnormalities. These results indicate that to evaluate PTEN
loss, both mechanisms of inactivation (mutation and deletion)
need to be considered, and they conﬁrm that PTEN abnormalities
are likely to be a contributory factor in the pathogenesis of a
signiﬁcant proportion of patients with T-ALL.
A striking feature of our study was the high proportion of
mutant-positive patients (67%) with more than one PTEN
mutation. In some cases, this may reﬂect compound hetero-
zygosity leading to complete absence of PTEN in a cell, but
approximately half of the cases were likely to have multiple minor
subclones. Similarly, the deletions in ﬁve of the six quantiﬁable
cases (83%) were not present in all cells, and the frequency of
gene deletions detected is probably under-estimated as the
methodologies used were not sufﬁciently sensitive to detect
low-level deletions. This is in keeping with the intratumoral
heterogeneity now being revealed by deep-sequencing studies35
and suggests that acquisition of a PTEN mutation or deletion is
more likely to be a later event associated with disease progression.
It will therefore be important to determine whether these PTENABN
clones are being selected for at relapse. Analysis of paired
diagnostic and relapse samples has demonstrated acquisition of
PTEN mutations and deletions at relapse,16,36 but whether these
are de novo changes or therapy-induced selection is unclear.
Back-tracking has shown that minor PTENABN clones can be
clonally expanded to become the dominant clone at relapse.3,36
Xenotransplantation studies have not consistently demonstrated
that loss of PTEN constitutes an adequate selection pressure for
driving this expansion,23,36 although in this setting, primary
leukemic cells with PTEN knocked down by short hairpin RNAs
did show a competitive engraftment advantage over the
unmodiﬁed cells.36 The signiﬁcance of speciﬁc abnormalities
may also be highly dependent on the presence of other
co-incident genetic events, and further work will be required to
determine whether this can be predicted from the genetic proﬁle
of individual cases.
Despite the data implicating the PI3K/AKT pathway as an
important oncogenic driver pathway in T-ALL, in pediatric
patients, there is currently little evidence to suggest that the
PTEN genotype is a strong prognostic factor. We found no
signiﬁcant association between PTEN abnormalities and either
response to therapy or long-term outcome in our cohort, and this
absence of an impact could not be attributed to therapy received
as the proportion of patients with/without PTEN abnormalities
treated on the different regimens did not differ, although it must
be acknowledged that the number of events is small and larger
studies may reveal more minor effects. There was a suggestion in
our study that PTEN abnormalities may be associated with a worse
OS and this is in general agreement with other pediatric
studies.12,13,20 A meta-analysis would be useful, but few studies
have reported both PTEN mutational and copy number status.
Adding patients with RAS mutations to the abnormal group made
no difference. Studies have suggested that the monoallelic loss of
PTENmay be more detrimental than biallelic loss, leading to tumor
progression rather than Pten-loss-induced cellular senescence.37
However, when our patients were stratiﬁed according to the level
of mutant or deletion, although PTENMONO patients were
associated with unfavorable levels of MRD and a worse OS, the
difference was not signiﬁcant and, in view of the small number of
patients in the subgroups, this would require validation in a larger
cohort.
Importantly, we found no evidence that the presence of a PTEN
abnormality impacted on the highly favorable outcome that we
previously reported in NOTCH1± FBXW7Double patients.8 Of note,
these results are in keeping with those from the pediatric ALL-BFM
2000 trial,13 but in distinct contrast to adult patients where a
signiﬁcantly adverse impact of PTEN/RAS abnormalities was found,
irrespective of NOTCH1/FBXW7 genotype.14 Applying the NOTCH1/
FBXW7/RAS/PTEN-based oncogenetic classiﬁcation criteria pro-
posed for adults to our pediatric cohort, which does not
discriminate between NOTCH1/FBXW7 double- and single-mutated
Table 3. Outcome at 5 years according to PTEN/RAS genotype in the NOTCH1/FBXW7 subgroups
NOTCH1/FBXW7 subgroup PTEN/RAS genotype RFS OS
Events/n % (95% CI) Pa Events/n % (95% CI) Pa
NOTCH1± FBXW7Double PTENWT 2/32 94% (77–98%) 0.57 0/32 100% N/Ab
PTENABN 0/5 100% 0/5 100%
PTEN/RASWT 2/28 93% (74–98%) 0.42 0/28 100% N/Ab
PTEN/RASABN 0/9 100% 0/9 100%
NOTCH1SingleFBXW7WT PTENWT 7/41 83% (67–93%) 0.68 4/41 90% (76–96%) 0.24
PTENABN 3/14 79% (47–93%) 3/14 79% (47–93%)
PTEN/RASWT 7/38 81% (64–91%) 0.98 4/38 89% (74–96%) 0.44
PTEN/RASABN 3/17 82% (55–94%) 3/17 82% (55–94%)
NOTCH1WTFBXW7WT PTENWT 5/36 85% (68–94%) 0.82 6/36 83% (67–92%) 0.60
PTENABN 3/13 83% (48–96%) 3/13 77% (47–93%)
PTEN/RASWT 5/33 87% (69–95%) 0.49 5/33 85% (67–93%) 0.39
PTEN/RASABN 4/16 80% (50–93%) 4/16 75% (46–90%)
Abbreviations: ABN, abnormal; CI, conﬁdence interval; OS, overall survival; RFS, relapse-free survival; WT, wild type. aP-values: Log-rank test. bNot applicable as
no deaths reported.
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patients,14 there was no difference in relapse rate between the
high-risk and low-risk groups and only a borderline difference in
OS, which could be attributed to better salvage of relapsed
patients in the low-risk group. This difference (94 versus 84%) was
small compared with the major difference seen in adult patients
(82 versus 44%) and with the small number of events involved, it
could have occurred by chance. Larger studies will be needed to
determine whether this classiﬁcation system is informative in
pediatric patients.
These results would therefore suggest that, at present, despite
PTEN loss being common in pediatric T-ALL, screening for PTEN
abnormalities at diagnosis would not add further information to
reﬁne the currently available risk-adapted therapy strategies.
However, with the current development and clinical evaluation of
many PI3K inhibitors,38 the PTEN genotype may serve as a
potential biomarker for response to these agents.
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